learn Osteopontin
signaling protein that, when suppressed, may grow hair by reducing inflammation and stem cell loss
Search
forProducts matching "androgen therapeutics"
Tracking 3 products like 257 RU58841 5% PG+ Ethanol, 260 RU58841 Powder and 260 RU58841 Powder from by companies like Anageninc. View all 3 products »Learn
5 / 16 resultslearn Bicalutamide
a nonsteroidal anti-androgen, most commonly used orally for women
learn Overview
learn Neem Oil
natural substance from Neem tree with medicinal and pesticidal properties
learn Epidermal Growth Factor
Research
5 / 1000+ resultsresearch President's Message
The meeting highlighted advances in sexual medicine and priapism management.
research Redefining Hormone Resistance in Prostate Cancer
The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.
research Synthesis and Application of Clinically Approved Small-Molecule Drugs Targeting Androgen Receptor
Drugs targeting the Androgen Receptor are effective for treating prostate cancer and other androgen-related conditions.
research Pharmacological Therapeutics in Androgenetic Alopecia
Minoxidil and finasteride are effective for treating hair loss, with dutasteride showing potential but with side effects.
research New Insights Into Molecular Signaling Pathways And Current Advancements In Prostate Cancer Diagnostics And Therapeutics
New drugs and therapies targeting specific pathways show promise in treating advanced prostate cancer.
Community Join
5 / 1000+ resultscommunity Eirion Therapeutics Announces Potential Breakthrough Treatment for Hair Loss Based on First-in-Man Clinical Trial Results
ET-02, a new hair loss treatment, shows promising results with a 6-fold increase in hair count, potentially outperforming minoxidil by activating stem cells in hair follicles. Further trials are ongoing to confirm its efficacy and safety, with potential market release in the future.
community GT20029 China Phase II Trial For AGA Reached Primary Endpoint
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
community What new hair-loss treatments actually look exciting right now (Oct 2025)
New hair loss treatments include Breezula, PP405, ET-02, KX-826, GT20029, VDPHL01, and CosmeRNA, with some showing promise in reactivating stem cells and reversing greying. Breezula and VDPHL01 are highlighted as potential add-ons or alternatives to current treatments like finasteride and minoxidil.
community Grey Market GT20029 and Frequency of Application
The conversation is about the potential release of GT20029 on the grey market and concerns about its safety and authenticity. One user advises waiting for the official release by Kintor.
community How to cope with starting fin/dut too late
Regret over not starting hair loss treatments like finasteride and minoxidil earlier, leading to significant hair loss. Users discuss coping strategies, including buzzing hair, staying on medications, and considering future treatments.